Epimmune Inc., of San Diego, appointed Michael Ross to its board.
Generex Biotechnology Corp., of Toronto, elected Steven Peltzman as vice president of business development and licensing.
Genesis Research and Development Corp., of Aukland, New Zealand, appointed Nathan Bach vice president, business development, responsible for expanding its plant sciences commercial activities in North America, and Benjamin Twombly vice president of business development, responsible for expanding its health sciences commercial activities in North America.
Gilead Sciences Inc., of Foster City, Calif., promoted John Milligan to senior vice president and chief financial officer.
Hybrigenics SA, of Paris, appointed Anne-Fabienne Weitsch chief operating officer.
ICN Pharmaceuticals Inc., of Costa Mesa, Calif., elected Roderick Hills to its board.
Intronn Inc., of Rockville, Md., appointed Edward Otto as chief operating officer.
Lehman Bros., of New York, hired John Chambers as a managing director of its global healthcare banking group.
LifeCell Corp., of Branchburg, N.J., added Jonathan Silverstein to its board.
MacroGenics Inc., of Rockville, Md., appointed Michael Richman executive vice president and chief operating officer and Kathryn Stein vice president for product development and regulatory affairs.
Merrimack Pharmaceuticals Inc., of Cambridge, Mass., added Mark Perrone as vice president of research and development.
NeoGenomics Inc., of Naples, Fla., appointed Steven Poliakoff to its scientific advisory board.
Novirio Pharmaceuticals Inc., of Cambridge, Mass., elected Wayne Hockmeyer to its board.
OncoGenex Technologies Inc., of Vancouver, British Columbia, appointed James Shepard, Julia Levy and Richard Glickman to its board.
Ontogen Corp., of Carlsbad, Calif., formed its oncology advisory group, consisting of Branimir Sikic as chairman, Neil Clendeninn, Daniel Hoth, Kenneth Krantz, Victor Ling and George Sledge.